Fig. 1.
AZT and IFN-α induce remission in a PEL patient.
(A) Primary tumor cells (BCLM) from an HHV-8+ PEL patient demonstrate typical phenotype of PEL. Surface expression of CD4, CD20, and CD30 on 1 × 106 cells from pleural fluid was determined by FACS analysis. (B) AZT and IFN-α induce remission in the PEL patient. Left: Chest x-ray of the same patient 2 days after diagnostic thoracentesis and before therapy with twice-daily parenteral AZT 1.5 g and IFN-α 5 million units. Middle: Chest x-ray 5 days after initiation of therapy. Right: Chest x-ray 1 month after therapy.
